165 related articles for article (PubMed ID: 38517707)
1. Prevalence and characteristics of ertapenem-mono-resistant isolates among carbapenem-resistant Enterobacterales in China.
Wang Y; Hu H; Shi Q; Zhang P; Zhao D; Jiang Y; Yu Y
Emerg Microbes Infect; 2024 Dec; 13(1):2332658. PubMed ID: 38517707
[TBL] [Abstract][Full Text] [Related]
2. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
Shortridge D; Kantro V; Castanheira M
Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
[TBL] [Abstract][Full Text] [Related]
3. Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant
Shropshire WC; Konovalova A; McDaneld P; Gohel M; Strope B; Sahasrabhojane P; Tran CN; Greenberg D; Kim J; Zhan X; Aitken S; Bhatti M; Savidge TC; Treangen TJ; Hanson BM; Arias CA; Shelburne SA
mSystems; 2022 Oct; 7(5):e0047622. PubMed ID: 36036505
[TBL] [Abstract][Full Text] [Related]
4. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
6. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
[TBL] [Abstract][Full Text] [Related]
7. Role of association of OmpK35 and OmpK36 alteration and bla
Hamzaoui Z; Ocampo-Sosa A; Fernandez Martinez M; Landolsi S; Ferjani S; Maamar E; Saidani M; Slim A; Martinez-Martinez L; Boutiba-Ben Boubaker I
Int J Antimicrob Agents; 2018 Dec; 52(6):898-905. PubMed ID: 29621592
[TBL] [Abstract][Full Text] [Related]
8. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
[TBL] [Abstract][Full Text] [Related]
9.
Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
[TBL] [Abstract][Full Text] [Related]
10. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
12. Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile.
Wozniak A; Villagra NA; Undabarrena A; Gallardo N; Keller N; Moraga M; Román JC; Mora GC; García P
J Med Microbiol; 2012 Sep; 61(Pt 9):1270-1279. PubMed ID: 22700549
[TBL] [Abstract][Full Text] [Related]
13. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
14. Performance evaluation of automated BD Phoenix NMIC-500 panel for carbapenemase detection in carbapenem-resistant and carbapenem-susceptible Enterobacterales.
Cho H; Kim JO; Choi JE; Lee H; Heo W; Cha YJ; Yoo IY; Park YJ
J Microbiol Methods; 2020 Oct; 177():106042. PubMed ID: 32890572
[TBL] [Abstract][Full Text] [Related]
15. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
Gupta V; Yu KC; Pogue JM; Watts JA; Clancy CJ
Microbiol Spectr; 2022 Jun; 10(3):e0115822. PubMed ID: 35638777
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization of Carbapenemase-Nonproducing Clinical Isolates of Escherichia coli (from a Thai University Hospital) with Reduced Carbapenem Susceptibility.
Nuramrum S; Chanawong A; Lunha K; Lulitanond A; Sangka A; Wilailuckana C; Angkititrakul S; Charoensri N; Wonglakorn L; Chaimanee P; Chetchotisakd P
Jpn J Infect Dis; 2017 Nov; 70(6):628-634. PubMed ID: 28890516
[TBL] [Abstract][Full Text] [Related]
17. New Delhi Metallo-β-lactamase and other mechanisms of carbapenemases among Enterobacteriaceae in rural South India.
Sekar R; Srivani S; Kalyanaraman N; Thenmozhi P; Amudhan M; Lallitha S; Mythreyee M
J Glob Antimicrob Resist; 2019 Sep; 18():207-214. PubMed ID: 31181271
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of phenotypic methods and polymerase chain reaction for the detection of carbapenemase production in clinical Klebsiella pneumoniae isolates].
Tekintaş Y; Çilli F; Eraç B; Yaşar M; Aydemir SŞ; Hoşgör Limoncu M
Mikrobiyol Bul; 2017 Jul; 51(3):269-276. PubMed ID: 28929963
[TBL] [Abstract][Full Text] [Related]
19. Molecular epidemiology of clinical isolation of carbapenem-resistant Enterobacterales and application of carbapenemase inhibitor enhancement test.
Li H; Zhong Y; Yan Q; Liu W; Liang X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 48(8):1210-1216. PubMed ID: 37875361
[TBL] [Abstract][Full Text] [Related]
20. IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort.
Shropshire WC; Aitken SL; Pifer R; Kim J; Bhatti MM; Li X; Kalia A; Galloway-Peña J; Sahasrabhojane P; Arias CA; Greenberg DE; Hanson BM; Shelburne SA
J Antimicrob Chemother; 2021 Jan; 76(2):385-395. PubMed ID: 33164081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
